Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant 20 mg for inhibition of atherosclerosis progression assessed by carotid artery intima-media thickness (CIMT) in overweight patients with additional risk factors
2005-001612-49Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerosis, Overweight and cardiac morbidity comparing Rimonabant 20 mg once daily with Placebo (2 arms). Primary endpoint: Absolute change in averaged carotid artery intima-media thickness (CIMT). Started Jul 2005; status: terminated.
02
Drugs
rimonabant
03
Conditions
atherosclerosisOverweightcardiac morbidity
Beyond the preview
Go deeper on 2005-001612-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001612-49.